Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia

NCT06624436 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT06624436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06624436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia
Lead sponsor
Radboud University Medical Center
Phase
Phase 4
Overall status
Recruiting
Start date
October 24, 2024
Completion date
December 31, 2025
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anakinra, dexamethasone, endotoxemia, immunosuppresion, neuroinflammatory response, sepsis, tocilizumab